DPP4 and Parkinson disease: Interestingly, a population-based cohort study revealed that PD incidence in patients with diabetes might vary according to their anti-diabetic treatment and that especially the use of GLP‐1 agonists and/or DPP-4 inhibitors are associated with a lower PD incidence (Brauer et al. 2020).